{"id":84902,"date":"2023-10-11T10:26:43","date_gmt":"2023-10-11T08:26:43","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=84902"},"modified":"2023-10-11T10:26:43","modified_gmt":"2023-10-11T08:26:43","slug":"agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/","title":{"rendered":"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline"},"content":{"rendered":"<p><strong> Agomab Therapeutics NV<\/strong> (\u2018Agomab\u2019) today announced the closing of a $100 million (\u20ac94.9 million) Series C financing round led by Fidelity Management &amp; Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.<\/p>\n<p>The new capital from the Series C financing will support the recently announced STENOVA Phase 2a clinical trial evaluating Agomab\u2019s lead candidate AGMB-129, a gut-restricted small molecule inhibitor of ALK5, in patients with Fibrostenosing Crohn\u2019s Disease (FSCD). In parallel to the start of the Phase 2a, AGMB-129 was also granted U.S. FDA Fast Track designation. Fibrotic strictures occur in up to 50% of Crohn\u2019s Disease patients and are the leading cause of bowel resection surgery, however there are no approved therapies for FSCD. Earlier this year, Agomab announced positive Phase 1 results showing that single- and multiple-dose oral AGMB-129 was safe and well-tolerated at all doses tested and confirming gastro-intestinal (GI)-restricted exposure.<\/p>\n<p>In addition, the proceeds will be used to advance and expand Agomab\u2019s portfolio of growth factortargeting drug candidates, including AGMB-447, a Phase 1-ready small molecule lung-restricted inhibitor of ALK5 for the treatment of Idiopathic Pulmonary Fibrosis and AGMB-101 and AGMB-102, cMET agonistic antibodies for the treatment of fibrotic and degenerative disorders. The proceeds will also enable strategic expansion of the organization and fund general corporate purposes.<\/p>\n<p>As part of the Series C funding round, Felice Verduyn &#8211; van Weegen, representing EQT, will join Agomab\u2019s Board of Directors, while Iyona Rajkomar, representing Dawn Biopharma, a platform controlled by KKR, and Colleen Cuffaro, representing Canaan, will join as Board Observers.<\/p>\n<p><em>\u201cWith the addition of these world-class investors we continue to build the company as a leader in the field of fibrosis and have secured the funding required to conduct clinical studies for multiple drug candidates,\u201d<\/em> <strong>said Tim Knotnerus, Chief Executive Officer at Agomab Therapeutics.<\/strong> <em>\u201cI am very pleased to be able to work with the new board to further develop our potentially game-changing therapeutics for the many patients in high need for anti-fibrotic therapies.\u201d<\/em><\/p>\n<p><em>\u201cWe have followed Tim and the team for years and believe that this is the right moment to join the company\u2019s journey,\u201d<\/em> <strong>added Felice Verduyn &#8211; van Weegen, Partner at EQT Life Sciences.<\/strong> <em>\u201cWe are very impressed by Agomab\u2019s scientific approach, strong team and mission to discover and develop drug candidates for fibrotic diseases, which remain underserved by current treatments available.\u201d<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Agomab Therapeutics NV (\u2018Agomab\u2019) today announced the closing of a $100 million (\u20ac94.9 million) Series C financing round led by Fidelity Management &amp; Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors. The new capital from the Series C financing will support&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-84902","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Agomab Therapeutics NV (\u2018Agomab\u2019) today announced the closing of a $100 million (\u20ac94.9 million) Series C financing round led by Fidelity Management &amp; Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors. The new capital from the Series C financing will support...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-11T08:26:43+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline\",\"datePublished\":\"2023-10-11T08:26:43+00:00\",\"dateModified\":\"2023-10-11T08:26:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/\"},\"wordCount\":414,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/\",\"name\":\"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2023-10-11T08:26:43+00:00\",\"dateModified\":\"2023-10-11T08:26:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/","og_locale":"fr_FR","og_type":"article","og_title":"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline - ANDERA PARTNERS","og_description":"Agomab Therapeutics NV (\u2018Agomab\u2019) today announced the closing of a $100 million (\u20ac94.9 million) Series C financing round led by Fidelity Management &amp; Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors. The new capital from the Series C financing will support...","og_url":"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2023-10-11T08:26:43+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline","datePublished":"2023-10-11T08:26:43+00:00","dateModified":"2023-10-11T08:26:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/"},"wordCount":414,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/","url":"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/","name":"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2023-10-11T08:26:43+00:00","dateModified":"2023-10-11T08:26:43+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/84902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=84902"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/84902\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=84902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=84902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}